[1] Rosenstein R, Empagliflozin HA. Cardiovascular outcomes, and mortality in type 2 diabetes.N Engl J Med, 2016, 374:1093-1094. [2] Tobias DK, Pan A, Jackson CL, et al. Body-mass index and mortality among adults with incident type 2 diabetes.N Engl J Med, 2014,370:233-244. [3] Younossi ZM, Koenig AB, Abdelatif D, et al. Global epide-miology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology, 2016,64:73-84. [4] Valenti L, Bugianesi E, Pajvani U, et al. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver Int, 2016, 36:1563-1579. [5] Wu S, Gao H, Ma Y, et al. Characterisation of betatrophin concentrations in childhood and adolescent obesity and insulin resistance. Pediat Diabetes, 2016, 17:53-60. [6] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2010, 18:163-166. [7] Andronescu CI, Purcarea MR, Babes PA. Nonalcoholic fatty liver disease: epidemiology, pathogenesis and therapeutic impli-cations. J Med Life, 2018, 11:20-23. [8] Lee CH, Lam KS. Managing nonalcoholic fatty liver disease in diabetes: Challenges and opportunities. J Diabetes Invest, 2017, 8:131-133. [9] Fukuda T, Hamaguchi M, Kojima T, et al. The impact of nonalcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals. Liver Int, 2016, 36:275-283. [10] 严克敏, 龚凤英. Betatrophin与胰岛β细胞增殖及糖脂代谢的关系. 国际内分泌代谢杂志, 2016, 36: 372-373. [11] 荣爱国. 新诊断2型糖尿病患者血清Betatrophin水平及其与代谢指标相关性分析. 检验医学与临床, 2016, 13:3177-3179. |